Tracy Stockley

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4538998/publications.pdf

Version: 2024-02-01

153 papers	3,788 citations	185998 28 h-index	149479 56 g-index
155 all docs	155 docs citations	155 times ranked	6884 citing authors

#	Article	IF	Citations
1	BCRâ€“ABL1 transcript doubling time as a predictor for treatmentâ€free remission failure after imatinib discontinuation in chronic myeloid leukaemia in chronic phase. British Journal of Haematology, 2022, 196, 136-145.	1.2	4
2	A clinical laboratoryâ€“developed LSC17 stemness score assay for rapid risk assessment of patients with acute myeloid leukemia. Blood Advances, 2022, 6, 1064-1073.	2.5	11
3	Integrating comprehensive genomic sequencing of non-small cell lung cancer into a public healthcare system. Cancer Treatment and Research Communications, 2022, 31, 100534.	0.7	3
4	Molecular yield and cytomorphologic assessment of fine needle aspiration specimen supernatants. Journal of the American Society of Cytopathology, 2022, 11, 142-153.	0.2	2
5	Comprehensive genomic profiling of treatment resistant metastatic castrate sensitive prostate cancer reveals high frequency of potential therapeutic targets. Clinical Genitourinary Cancer, 2022, , .	0.9	1
6	VHL mosaicism: the added value of multi-tissue analysis. Npj Genomic Medicine, 2022, 7, 21.	1.7	7
7	Clinical Application of Next-Generation Sequencing in Advanced Thyroid Cancers. Thyroid, 2022, 32, 657-666.	2.4	16
8	Practice guidelines for BRCA1/2 tumour testing in ovarian cancer. Journal of Medical Genetics, 2022, 59, 727-736.	1.5	4
9	Turnaround Times in Melanoma BRAF Testing and the Impact on the Initiation of Systemic Therapy at a Single Tertiary Care Cancer Center. JCO Oncology Practice, 2022, , OP2100810.	1.4	1
10	Clinical and molecular correlates of JAK-inhibitor therapy failure in myelofibrosis: long-term data from a molecularly annotated cohort. Leukemia, 2022, 36, 1689-1692.	3.3	4
11	Reflex BRCA1 and BRCA2 tumour genetic testing for high-grade serous ovarian cancer: streamlined for clinicians but what do patients think?. Hereditary Cancer in Clinical Practice, 2022, 20, 15.	0.6	2
12	The 17â€gene stemness score associates with relapse risk and longâ€term outcomes following allogeneic haematopoietic cell transplantation in acute myeloid leukaemia. EJHaem, 2022, 3, 873-884.	0.4	2
13	Upfront Next Generation Sequencing in Non-Small Cell Lung Cancer. Current Oncology, 2022, 29, 4428-4437.	0.9	5
14	Plasma first: Accelerating lung cancer diagnosis through liquid biopsy.. Journal of Clinical Oncology, 2022, 40, 3039-3039.	0.8	0
15	Consensus Recommendations to Optimize Testing for New Targetable Alterations in Non-Small Cell Lung Cancer. Current Oncology, 2022, 29, 4981-4997.	0.9	14
16	Optimizing the delivery of genetic and advanced diagnostic testing in the province of Ontario: challenges and implications for laboratory technology assessment and management in decentralized healthcare systems. Journal of Medical Economics, 2022, 25, 993-1004.	1.0	1
17	Clinical implementation of circulating tumour DNA testing for EGFR T790M for detection of treatment resistance in non-small cell lung cancer. Journal of Clinical Pathology, 2021, 74, 91-97.	1.0	20
18	Tumor and germline next generation sequencing in high grade serous cancer: experience from a large populationâ€based testing program. Molecular Oncology, 2021, 15, 80-90.	2.1	14

#	Article	IF	Citations
19	Across barriers: poly ADP-ribose polymerase inhibitors beyond progression in high grade serous ovarian cancer with brain metastases. International Journal of Gynecological Cancer, 2021, 31, 139-143.	1.2	6
20	Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer: a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet, The, 2021, 397, 281-292.	6.3	125
21	FP07.08 A Pan-Canadian Validation Study for the Detection of EGFR-T790M Mutations Using Circulating Tumour DNA (ctDNA) from Blood. Journal of Thoracic Oncology, 2021, 16, S206-S207.	0.5	0
22	Consensus Recommendations for MRD Testing in Adult B-Cell Acute Lymphoblastic Leukemia in Ontario. Current Oncology, 2021, 28, 1376-1387.	0.9	7
23	Prognostic impact of the adverse molecular-genetic profile on long-term outcomes following allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia. Bone Marrow Transplantation, 2021, 56, 1908-1918.	1.3	10
24	77TiP From liquid biopsy to cure: Using CtDNA detection of minimal residual disease to identify patients for curative therapy after non-small cell lung cancer (NSCLC) resection. Journal of Thoracic Oncology, 2021, 16, S736.	0.5	3
25	191TiP Accelerating lung cancer diagnosis through liquid biopsy. Journal of Thoracic Oncology, 2021, 16, S801-S802.	0.5	0
26	Optimal duration of imatinib treatment/deep molecular response for treatmentâ€free remission after imatinib discontinuation from a Canadian tyrosine kinase inhibitor discontinuation trial. British Journal of Haematology, 2021, 193, 779-791.	1.2	10
27	The value of defining molecular resistance in patients with progressive EGFR and ALK-driven lung cancer in a public system.. Journal of Clinical Oncology, 2021, 39, 3126-3126.	0.8	0
28	Preliminary results of BEAVER: An investigator-initiated phase II study of binimetinib and encorafenib for the treatment of advanced solid tumors with non-V600E BRAF mutations (mts).. Journal of Clinical Oncology, 2021, 39, e15038-e15038.	0.8	2
29	Can TP53 variant negative be high-grade serous ovarian carcinoma? A case series. Gynecologic Oncology Reports, 2021, 36, 100729.	0.3	1
30	Personalized Risk Assessment for Prevention and Early Detection of Breast Cancer: Integration and Implementation (PERSPECTIVE I&I). Journal of Personalized Medicine, 2021, 11, 511.	1.1	59
31	Validation of BRCA testing on cytologic samples of highâ€grade serous carcinoma. Cancer Cytopathology, 2021, 129, 907-913.	1.4	2
32	A phase I study of binimetinib (MEK 162), a MEK inhibitor, plus carboplatin and pemetrexed chemotherapy in non-squamous non-small cell lung cancer. Lung Cancer, 2021, 157, 21-29.	0.9	8
33	The Prevent Ovarian Cancer Program (POCP): Identification of women at risk for ovarian cancer using complementary recruitment approaches. Gynecologic Oncology, 2021, 162, 97-106.	0.6	3
34	Phase II Trial of Trametinib and Panitumumab in RAS/RAF Wild Type Metastatic Colorectal Cancer. Clinical Colorectal Cancer, 2021, 20, 334-341.	1.0	9
35	A Pan-Canadian Validation Study for the Detection of EGFR T790M Mutation Using Circulating Tumor DNA From Peripheral Blood. JTO Clinical and Research Reports, 2021, 2, 100212.	0.6	2
36	Should Age-Dependent Absolute Risk Thresholds Be Used for Risk Stratification in Risk-Stratified Breast Cancer Screening?. Journal of Personalized Medicine, 2021, 11, 916.	1.1	8

#	Article	IF	Citations
37	805P Clinically actionable alterations in adolescents and young adults (AYA) with gynaecological cancers. Annals of Oncology, 2021, 32, S764.	0.6	0
38	531P Binimetinib and encorafenib for the treatment of advanced solid tumors with non-V600E BRAF mutations (mts): Preliminary results of the investigator initiated phase II BEAVER trial. Annals of Oncology, 2021, 32, S596.	0.6	1
39	Canadian ROS proto-oncogene 1 study (CROS) for multi-institutional implementation of ROS1 testing in non-small cell lung cancer. Lung Cancer, 2021, 160, 127-135.	0.9	16
40	Genomic characterization of non-schistosomiasis-related squamous cell carcinoma of the urinary bladder: A retrospective exploratory study. PLoS ONE, 2021, 16, e0259272.	1.1	4
41	Year 1: Experiences of a tertiary cancer centre following implementation of reflex BRCA1 and BRCA2 tumor testing for all high-grade serous ovarian cancers in a universal healthcare system. Gynecologic Oncology, 2020, 158, 747-753.	0.6	12
42	Multicenter Validation Study to Implement Plasma Epidermal Growth Factor Receptor T790M Testing in Clinical Laboratories. JCO Precision Oncology, 2020, 4, 520-533.	1.5	9
43	ALK-rearranged lung adenocarcinoma transformation into high-grade large cell neuroendocrine carcinoma: Clinical and molecular description of two cases. Lung Cancer, 2020, 146, 350-354.	0.9	14
44	Poly (ADP Ribose) Polymerase Inhibitors for Cancer. Journal of Molecular Diagnostics, 2020, 22, 1126-1128.	1.2	0
45	Optimizing management of advanced urothelial carcinoma: A review of emerging therapies and biomarker-driven patient selection. Canadian Urological Association Journal, 2020, 14, E373-E382.	0.3	8
46	Assessing the Diagnostic Yield of Targeted Next-Generation Sequencing for Melanoma and Gastrointestinal Tumors. Journal of Molecular Diagnostics, 2020, 22, 467-475.	1.2	5
47	Molecular profiling for precision cancer therapies. Genome Medicine, 2020, 12, 8.	3.6	447
48	Measurable residual disease monitoring provides insufficient lead-time to prevent morphologic relapse in the majority of patients with core-binding factor acute myeloid leukemia. Haematologica, 2020, 106, 56-63.	1.7	23
49	Exomes and transcriptomes to reveal actionable findings in patients with negative-targeted panel sequencing.. Journal of Clinical Oncology, 2020, 38, 3562-3562.	0.8	1
50	Consensus Recommendations for Optimizing Biomarker Testing to Identify and Treat Advanced EGFR-Mutated Non-Small-Cell Lung Cancer. Current Oncology, 2020, 27, 321-329.	0.9	20
51	Genomic analysis of driver-negative lung adenocarcinoma (LA) in lifetime never smokers.. Journal of Clinical Oncology, 2020, 38, 3571-3571.	0.8	0
52	Comprehensive genomic profiling (CGP) of metastatic castrate-sensitive prostate cancer (mCSPC) to reveal potential biomarkers and therapeutic targets.. Journal of Clinical Oncology, 2020, 38, 198-198.	0.8	0
53	Inferior Outcomes with a High LSC17 Score Can be Improved with Flag-IDA. Blood, 2020, 136, 35-36.	0.6	0
54	BCR-ABL1 Transcript Doubling Time after Imatinib Discontinuation for Treatment-Free Remission in Chronic Myeloid Leukemia in Chronic Phase: Predictor for Treatment-Free Remission Failure. Blood, 2020, 136, 40-41.	0.6	1

#	Article	IF	Citations
55	Optimal Duration of Imatinib Treatment / Deep Molecular Response for Treatment-Free Remission after Imatinib Discontinuation from a Canadian Tyrosine Kinase Inhibitor Discontinuation Trial. Blood, 2020, 136, 54-55.	0.6	0
56	P53 Gene Mutation Identified by Next Generation Sequencing in Poorly Differentiated Neuroendocrine Carcinoma of the Nasal Cavity. Head and Neck Pathology, 2019, 13, 516-522.	1.3	1
57	Comprehensive characterization of a Canadian cohort of von Hippelâ€Lindau disease patients. Clinical Genetics, 2019, 96, 461-467.	1.0	16
58	Molecular characterization of gastric-type endocervical adenocarcinoma using next-generation sequencing. Modern Pathology, 2019, 32, 1823-1833.	2.9	52
59	Phase II trial of trametinib (T) and panitumumab (Pmab) in RAS/RAF wild type (wt) metastatic colorectal cancer (mCRC). Annals of Oncology, 2019, 30, v232-v233.	0.6	1
60	Crizotinib Inhibition of ROS1-Positive Tumours in Advanced Non-Small-Cell Lung Cancer: A Canadian Perspective. Current Oncology, 2019, 26, 551-557.	0.9	12
61	OCTANE (Ontario-Wide Cancer Targeted Nucleic Acid Evaluation): A Platform for Intraprovincial, National, and International Clinical Data-Sharing. Current Oncology, 2019, 26, 618-623.	0.9	9
62	Delayed Hematologic Recovery in AML Patients After Induction Chemotherapy is Associated with Inferior Relapse-Free Survival and Persistence of Preleukemic Mutations. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, S229-S230.	0.2	0
63	Modified panel-based genetic counseling for ovarian cancer susceptibility: A randomized non-inferiority study. Gynecologic Oncology, 2019, 153, 108-115.	0.6	15
64	A Canadian Guideline on the Use of Next-Generation Sequencing in Oncology. Current Oncology, 2019, 26, 241-254.	0.9	34
65	TP53 mutations in high grade serous ovarian cancer and impact on clinical outcomes: a comparison of next generation sequencing and bioinformatics analyses. International Journal of Gynecological Cancer, 2019, 29, 346-352.	1.2	29
66	The presence and variant allele fraction of EGFR mutations in ctDNA and development of resistance. Lung Cancer, 2019, 131, 86-89.	0.9	14
67	Impact of somatic molecular profiling on clinical trial outcomes in rare epithelial gynecologic cancer patients. Gynecologic Oncology, 2019, 153, 304-311.	0.6	7
68	The Somatic Curation and Interpretation Across Laboratories (SOCIAL) Projectâ€"Current State of Solid-Tumour Variant Interpretation for Molecular Pathology in Canada. Current Oncology, 2019, 26, 353-360.	0.9	6
69	Impact of preleukemic mutations and their persistence on hematologic recovery after induction chemotherapy for AML. Blood Advances, 2019, 3, 2307-2311.	2.5	12
70	CCMG practice guideline: laboratory guidelines for next-generation sequencing. Journal of Medical Genetics, 2019, 56, 792-800.	1.5	29
71	The prevent ovarian cancer program (POCP): Identification of ovarian cancer-associated mutations in self-referring women from low-risk families. Gynecologic Oncology, 2019, 154, 78.	0.6	0
72	Inter-Laboratory Proficiency Testing Scheme for Tumour Next-Generation Sequencing in Ontario: A Pilot Study. Current Oncology, 2019, 26, 717-732.	0.9	5

#	Article	IF	Citations
73	Effect of Coexisting KRAS and TP53 Mutations in Patients Treated With Chemotherapy for Nonâ€“small-cell Lung Cancer. Clinical Lung Cancer, 2019, 20, e338-e345.	1.1	14
74	Somatic Tumor Variant Filtration Strategies to Optimize Tumor-Only Molecular Profiling Using Targeted Next-Generation Sequencing Panels. Journal of Molecular Diagnostics, 2019, 21, 261-273.	1.2	36
75	Heterogenous loss of mismatch repair (MMR) protein expression: a challenge for immunohistochemical interpretation and microsatellite instability (MSI) evaluation. Journal of Pathology: Clinical Research, 2019, 5, 115-129.	1.3	96
76	Trial in Progress: Feasibility and Validation Study of the LSC17 Score in Acute Myeloid Leukemia Patients. Blood, 2019, 134, 2682-2682.	0.6	6
77	Non-small cell lung cancer (NSCLC) next generation sequencing (NGS) using the Oncomine Comprehensive Assay (OCA) v3: Integrating expanded genomic sequencing into the Canadian publicly funded health care model.. Journal of Clinical Oncology, 2019, 37, 2620-2620.	0.8	9
78	PS1027 ASSESSMENT OF MOLECULAR MRD KINETICS BY ERRORâ€CORRECTED NEXTâ€GENERATION SEQUENCING PROVIDES INDEPENDENT PROGNOSTIC INFORMATION IN ADULT AML PATIENTS. HemaSphere, 2019, 3, 463.	1.2	0
79	High Interpatient Variability in Molecular MRD Response to Consolidation Chemotherapy in Acute Myeloid Leukemia. Blood, 2019, 134, 1424-1424.	0.6	0
80	AML refractory to primary induction with Ida-FLAG has a poor clinical outcome. Leukemia Research, 2018, 68, 22-28.	0.4	7
81	Improving validation methods for molecular diagnostics: application of Bland-Altman, Deming and simple linear regression analyses in assay comparison and evaluation for next-generation sequencing. Journal of Clinical Pathology, 2018, 71, 117-124.	1.0	7
82	Identifying actionable variants using next generation sequencing in patients with a historical diagnosis of undifferentiated pleomorphic sarcoma. International Journal of Cancer, 2018, 142, 57-65.	2.3	23
83	Impact of multi-gene mutational profiling on clinical trial outcomes in metastatic breast cancer. Breast Cancer Research and Treatment, 2018, 168, 159-168.	1.1	27
84	Minimally Invasive Real-Time Detection of Actionable Mutations in Patients With Metastatic Solid Tumors Using Fine-Needle and Liquid Biopsies. JCO Precision Oncology, 2018, 2, 1-20.	1.5	0
85	P2.03-03 Upfront Next Generation Sequencing in NSCLC: A Publicly Funded Perspective. Journal of Thoracic Oncology, 2018, 13, S717.	0.5	0
86	Distinct patterns of clonal evolution in patients with concurrent myelo- and lymphoproliferative neoplasms. Blood, 2018, 132, 2201-2205.	0.6	4
87	The mutational landscape of accelerated- and blast-phase myeloproliferative neoplasms impacts patient outcomes. Blood Advances, 2018, 2, 2658-2671.	2.5	47
88	Evolution of genetic assessment for BRCA-associated gynaecologic malignancies: a Canadian multisociety roadmap. Journal of Medical Genetics, 2018, 55, 571-577.	1.5	33
89	Clinical Utility of Nextâ€generation Sequencing in the Management of Myeloproliferative Neoplasms: A Singleâ€Center Experience. HemaSphere, 2018, 2, e44.	1.2	19
90	Evidence-Based Best Practices for EGFR T790M Testing in Lung Cancer in Canada. Current Oncology, 2018, 25, 163-169.	0.9	28

#	Article	IF	Citations
91	Additional germline findings from a tumor profiling program. BMC Medical Genomics, 2018, 11, 65.	0.7	16
92	A Clinical and Molecular Phase II Trial of Oral ENMD-2076 in Ovarian Clear Cell Carcinoma (OCCC): A Study of the Princess Margaret Phase II Consortium. Clinical Cancer Research, 2018, 24, 6168-6174.	3.2	44
93	Molecular Residual Disease Monitoring Provides Insufficient Lead-Time to Prevent Morphologic Relapse in the Majority of Patients with Core-Binding Factor AML. Blood, 2018, 132, 436-436.	0.6	1
94	Upfront next generation sequencing in NSCLC: A publicly funded perspective.. Journal of Clinical Oncology, 2018, 36, 12062-12062.	0.8	2
95	Detection of EGFR mutations in cfDNA and development of resistance.. Journal of Clinical Oncology, 2018, 36, e21072-e21072.	0.8	0
96	Delayed Hematologic Recovery in AML Patients after Induction Chemotherapy Is Associated with Inferior Relapse-Free Survival and Persistence of Preleukemic Mutations. Blood, 2018, 132, 992-992.	0.6	0
97	Impact of Genetic Profile on Clinical Outcomes in Adults â‰¥60 with AML: The Princess Margaret Cancer Centre Experience. Blood, 2018, 132, 2666-2666.	0.6	0
98	Genotype-matched treatment for patients with advanced type I epithelial ovarian cancer (EOC). Gynecologic Oncology, 2017, 144, 250-255.	0.6	27
99	Integration of Technical, Bioinformatic, and Variant Assessment Approaches in the Validation of a Targeted Next-Generation Sequencing Panel for Myeloid Malignancies. Archives of Pathology and Laboratory Medicine, 2017, 141, 759-775.	1.2	29
100	Data resources for the identification and interpretation of actionable mutations by clinicians. Annals of Oncology, 2017, 28, 946-957.	0.6	20
101	Impact of genomic alterations on outcomes in myelofibrosis patients undergoing JAK1/2 inhibitor therapy. Blood Advances, 2017, 1, 1729-1738.	2.5	48
102	Strategic Planning in an Academic Radiation Medicine Program. Current Oncology, 2017, 24, 518-523.	0.9	4
103	CHARGE and Kabuki Syndromes: Gene-Specific DNA Methylation Signatures Identify Epigenetic Mechanisms Linking These Clinically Overlapping Conditions. American Journal of Human Genetics, 2017, 100, 773-788.	2.6	166
104	Phase II clinical and molecular trial of oral ENMD-2076 in clear cell ovarian cancer (CCOC): A study of the Princess Margaret phase II consortium.. Journal of Clinical Oncology, 2017, 35, 5522-5522.	0.8	6
105	Genomic Profiling and Matched Therapy for Recurrent or Metastatic Malignant Salivary Gland Tumors (MSGT): Preliminary Results. International Journal of Radiation Oncology Biology Physics, 2016, 94, 947-948.	0.4	0
106	Establishment and Characterization of a Human Neuroendocrine Tumor Xenograft. Endocrine Pathology, 2016, 27, 97-103.	5.2	14
107	Testing ERBB2 p.L755S kinase domain mutation as a druggable target in a patient with advanced colorectal cancer. Journal of Physical Education and Sports Management, 2016, 2, a001016.	0.5	5
108	Comparison of Next-Generation Sequencing Panels and Platforms for Detection and Verification of Somatic Tumor Variants for Clinical Diagnostics. Journal of Molecular Diagnostics, 2016, 18, 842-850.	1.2	35

#	Article	IF	Citations
109	Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial. Genome Medicine, 2016, 8, 109.	3.6	211
110	Germline and somatic multi-gene sequencing in patients (pts) with advanced high grade serous ovarian cancer (HGSOC) and triple negative breast cancer (TNBC). Annals of Oncology, 2016, 27, vi535.	0.6	0
111	A classification system for clinical relevance of somatic variants identified in molecular profiling of cancer. Genetics in Medicine, 2016, 18, 128-136.	1.1	83
112	Incidental germline findings identified in a somatic genomic sequencing program for advanced cancer patients.. Journal of Clinical Oncology, 2016, 34, 1532-1532.	0.8	2
113	Integration of somatic molecular profiling for rare epithelial gynaecologic cancer patients.. Journal of Clinical Oncology, 2016, 34, 5509-5509.	0.8	0
114	Germline and somatic homologous recombination gene mutations in high-grade serous ovarian cancer and clinical outcome.. Journal of Clinical Oncology, 2016, 34, 5579-5579.	0.8	0
115	P53 functional mutation type in high-grade serous ovarian cancer and clinical outcomes.. Journal of Clinical Oncology, 2016, 34, 5550-5550.	0.8	0
116	Utility of Next Generation Sequencing in Prognostication and Therapeutic Decision Making in Cytogenetically Normal AML with DNMT3A Mutations. Blood, 2016, 128, 2886-2886.	0.6	2
117	Impact of Genomic Alterations on Outcomes in Myelofibrosis Patients Undergoing JAK1/2 Inhibitor Therapy. Blood, 2016, 128, 4263-4263.	0.6	0
118	15q11.2 Duplication Encompassing Only theUBE3AGene Is Associated with Developmental Delay and Neuropsychiatric Phenotypes. Human Mutation, 2015, 36, 689-693.	1.1	67
119	Whole-exome analysis of foetal autopsy tissue reveals a frameshift mutation in OBSL1, consistent with a diagnosis of 3-M Syndrome. BMC Genomics, 2015, 16, S12.	1.2	9
120	MG-131â€...Incidental germline findings in tumour molecular profiling by next generation sequencing. Journal of Medical Genetics, 2015, 52, A8.3-A9.	1.5	0
121	Whole-Exome Sequencing and Targeted Copy Number Analysis in Primary Ciliary Dyskinesia. G3: Genes, Genomes, Genetics, 2015, 5, 1775-1781.	0.8	53
122	The clinical application of genome-wide sequencing for monogenic diseases in Canada: Position Statement of the Canadian College of Medical Geneticists. Journal of Medical Genetics, 2015, 52, 431-437.	1.5	187
123	Prospective Next-Generation Sequencing Molecular Profiling of Myeloid Malignancies: Assessment of Information Benefit and Impact on Patient Care. Blood, 2015, 126, 3848-3848.	0.6	1
124	Periventricular nodular heterotopia and transverse limb reduction defect in a woman with interstitial 11q24 deletion in the Jacobsen syndrome region. American Journal of Medical Genetics, Part A, 2014, 164, 511-515.	0.7	18
125	X-Linked Hearing Loss: Two Gene Mutation Examples Provide Generalizable Implications for Clinical Care. American Journal of Audiology, 2014, 23, 190-200.	0.5	11
126	Paternal germline mosaicism for a GPC3 deletion in Xâ€linked Simpsonâ€Golabiâ€Behmel syndrome. American Journal of Medical Genetics, Part A, 2014, 164, 2682-2684.	0.7	3

#	Article	IF	Citations
127	A Novel Deletion inSMPXCauses a Rare form of X-Linked Progressive Hearing Loss in Two Families Due to a Founder Effect. Human Mutation, 2013, 34, 66-69.	1.1	21
128	Danon Disease Due to a Novel LAMP2 Microduplication. JIMD Reports, 2013, 14, 11-16.	0.7	8
129	CDKN1C mutations and genital anomalies. American Journal of Medical Genetics, Part A, 2012, 158A, 265-265.	0.7	3
130	Multiple effects of childhood deafness on cortical activity in children receiving bilateral cochlear implants simultaneously. Clinical Neurophysiology, 2011, 122, 823-833.	0.7	27
131	Pediatric cholesteatoma and variants in the gene encoding connexin 26. Laryngoscope, 2010, 120, 183-187.	1.1	10
132	Prevalence of Connexin 26 (GJB2) and Pendred (SLC26A4) Mutations in a Population of Adult Cochlear Implant Candidates. Otology and Neurotology, 2010, 31, 919-922.	0.7	16
133	Novel duplication in glypicanâ€4 as an apparent cause of Simpsonâ€“Golabiâ€“Behmel syndrome. American Journal of Medical Genetics, Part A, 2010, 152A, 3179-3181.	0.7	41
134	The role of molecular microsatellite identity testing to detect sampling errors in prenatal diagnosis. Prenatal Diagnosis, 2010, 30, 746-752.	1.1	10
135	A recurrent EYA1 mutation causing alternative RNA splicing in branchioâ€otoâ€renal syndrome: Implications for molecular diagnostics and disease mechanism. American Journal of Medical Genetics, Part A, 2009, 149A, 322-327.	0.7	15
136	Successful cochlear implantation in a child with Keratosis, Icthiosis and Deafness (KID) Syndrome and Dandy-Walker malformation. International Journal of Pediatric Otorhinolaryngology, 2008, 72, 693-698.	0.4	22
137	Urinary globotriaosylceramide excretion correlates with the genotype in children and adults with Fabry disease. Molecular Genetics and Metabolism, 2008, 93, 331-340.	0.5	88
138	Novel Mutation of the Perforin Gene and Maternal Uniparental Disomy 10 in a Patient With Familial Hemophagocytic Lymphohistiocytosis. Journal of Pediatric Hematology/Oncology, 2008, 30, 621-624.	0.3	14
139	Pyrimethamine as a Potential Pharmacological Chaperone for Late-onset Forms of GM2 Gangliosidosis. Journal of Biological Chemistry, 2007, 282, 9150-9161.	1.6	152
140	Craniosynostosis associated with distal 5qâ€trisomy: Further evidence that extra copy of MSX2 gene leads to craniosynostosis. American Journal of Medical Genetics, Part A, 2007, 143A, 2931-2936.	0.7	22
141	In Reference toTemporal Bone Imaging inGJB2Deafness. Laryngoscope, 2007, 117, 1127-1129.	1.1	6
142	Strategy for Comprehensive Molecular Testing for Duchenne and Becker Muscular Dystrophies. Genetic Testing and Molecular Biomarkers, 2006, 10, 229-243.	1.7	32
143	Ethnicity and mutations in GJB2 (connexin 26) and GJB6 (connexin 30) in a multi-cultural Canadian paediatric Cochlear Implant Program. International Journal of Pediatric Otorhinolaryngology, 2006, 70, 435-444.	0.4	30
144	Auditory Responses in Cochlear Implant Users With and Without GJB2 Deafness. Laryngoscope, 2006, 116, 317-327.	1.1	41

#	Article	IF	Citations
145	Temporal Bone Imaging in GJB2 Deafness. Laryngoscope, 2006, 116, 2178-2186.	1.1	37
146	The Natural History of Juvenile or Subacute GM2 Gangliosidosis: 21 New Cases and Literature Review of 134 Previously Reported. Pediatrics, 2006, 118, e1550-e1562.	1.0	165
147	Functional disomy of Xp: Prenatal findings and postnatal outcome. American Journal of Medical Genetics, Part A, 2005, 134A, 393-398.	0.7	13
148	Providing information at the point of care: educational diagnostic reports from a genetic testing service provider. Clinical Leadership and Management Review, 2004, 18, 11-24.	0.0	3
149	Multiplexed Fluorescence Analysis for Mutations Causing Tay-Sachs Disease. , 2003, 217, 131-142.		1
150	Discordant KCNQ1OT1 imprinting in sets of monozygotic twins discordant for Beckwith-Wiedemann syndrome. Human Molecular Genetics, 2002, 11, 1317-1325.	1.4	322
151	Parents of children with spinal muscular atrophy are not obligate carriers: Carrier testing is important for reproductive decision-making. American Journal of Medical Genetics Part A, 2002, 107, 247-249.	2.4	14
152	Delivery of recombinant product from subcutaneous implants of encapsulated recombinant cells in canines. Translational Research, 2000, 135, 484-492.	2.4	12
153	The in vivo delivery of heterologous proteins by microencapsulated recombinant cells. Trends in Biotechnology, 1999, 17, 78-83.	4.9	73